GOSS vs MNKD vs UTHR vs NKTR vs IQV vs JPM

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -57. 7% for Gossamer Bio, Inc. (GOSS). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Gossamer Bio, Inc. (GOSS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus MannKind Corporation at 183. 0x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus United Therapeutics Corporation's 1. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, United Therapeutics Corporation (UTHR) delivered a total return of +203.

9%, compared to -98. 2% for Gossamer Bio, Inc. (GOSS). Over 10 years, the gap is even starker: JPM returned +465. 8% versus GOSS's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.

14β versus Gossamer Bio, Inc. 's 2. 45β — meaning GOSS is approximately 1707% more volatile than UTHR relative to the S&P 500. On balance sheet safety, Nektar Therapeutics (NKTR) carries a lower debt/equity ratio of 166% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -57. 7% for Gossamer Bio, Inc. (GOSS). On earnings-per-share growth, the picture is similar: United Therapeutics Corporation grew EPS 13. 1% year-over-year, compared to -200. 0% for Gossamer Bio, Inc.. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -351. 5% for Gossamer Bio, Inc. — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 47. 7% versus -336. 8% for GOSS. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus United Therapeutics Corporation's 1. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 19. 2x for United Therapeutics Corporation — 5. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GOSS: 373. 6% to $0. 77.

In this comparison, JPM (1.

9% yield) pays a dividend. GOSS, MNKD, UTHR, NKTR, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

14), +396. 1% 10Y return). Gossamer Bio, Inc. (GOSS) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTHR: +396. 1%, GOSS: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GOSS (Healthcare) and MNKD (Healthcare) and UTHR (Healthcare) and NKTR (Healthcare) and IQV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GOSS is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock; UTHR is a mid-cap quality compounder stock; NKTR is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while GOSS, MNKD, UTHR, NKTR, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.